678144-96-2

Upstream product

• 638-29-9 n-valeryl chloride 
• 678144-89-3 3-(4-{[6-(benzylamino)-4-oxo-2-propyl-3,4-dihydroquinazolin-3-yl]methyl}phenyl)-N-tert-butyl-5-isobutylthiophene-2-sulfonamide 
• 100-52-7 benzaldehyde 
• 156483-24-8 3-(4-bromobenzyl)-6-nitro-2-propyl-3,4-dihydroquinazolin-4-one 
• 163520-14-7 5-isobutyl-2 -(tert-butylaminosulfonyl)-3-thiopheneboronic acid 
• 678144-77-9 3-{4-[(6-amino-4-oxo-2-propyl-3,4-dihydroquinazolin-3-yl)methyl]phenyl}-N-tert-butyl-5-isobutylthiophene-2-sulfonamide 
• 678144-71-3 N-tert-butyl-5-isobutyl-3-{4-[(6-nitro-4-oxo-2-propyl-3,4-dihydroquinazolin-3-yl)methyl]phenyl}thiophene-2-sulfonamide 

Relevant academic research and scientific papers

First Reported Nonpeptide AT1 Receptor Agonist (L-162,313) Acts as an AT2 Receptor Agonist in Vivo

In this investigation, it is demonstrated that the first nonpeptide AT 1 receptor agonist L-162,313 (1), disclosed in 1994, also acts as an agonist at the AT2 receptor. In anesthetized rats, administration of compound 1 intravenously